After abandoning research efforts deemed futile in March, Biotech giant Biogen is trying again. It intends to seek approval from the U.S. Food and Drug Administration for a medication that appears to slow the decline of Alzheimer’s patients. Two smaller studies had shown no benefit, but a fresh analysis of more data showed the drug, called aducanumab, to be “pharmacologically and clinically active.” Meanwhile, Biogen stock jumped 37 percent on the news.
Will it be approved? Some analysts say a single positive trial isn’t quite convincing enough, while the Alzheimer’s Association said it had “never been as optimistic.”